Seres Therapeutics, Inc.
MCRB
$7.84
-$0.12-1.51%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 24.79% | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 24.79% | -- | |||
| Cost of Revenue | 2,451.60% | -87.61% | |||
| Gross Profit | -3,034.63% | 90.01% | |||
| SG&A Expenses | -20.44% | -7.58% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -13.20% | -8.25% | |||
| Operating Income | 13.79% | 9.66% | |||
| Income Before Tax | -286.92% | 141.32% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -286.92% | 141.32% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -286.92% | 141.32% | |||
| EBIT | 13.79% | 9.66% | |||
| EBITDA | 14.04% | 10.03% | |||
| EPS Basic | -277.38% | 141.25% | |||
| Normalized Basic EPS | 17.16% | 5.26% | |||
| EPS Diluted | -277.38% | 141.25% | |||
| Normalized Diluted EPS | 17.04% | 5.40% | |||
| Average Basic Shares Outstanding | 5.38% | 0.17% | |||
| Average Diluted Shares Outstanding | 5.22% | 0.32% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||